FindTrial
Sign In

Phase III study of T-3262G15% in the pediatric patients with mycoplasma pneumonia

Phase III study of T-3262G15% in the pediatric patients with mycoplasma pneumonia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222224
Enrollment
Unknown
Registered
2013-09-17
Start date
2013-09-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma pneumonia

Interventions

investigational material(s) Generic name etc : T-3262G15% (Tosufloxacin Tosilate Hydrate) INN of investigational material : Tosufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Age: between 1 and 15 years old (2) Sex: male or female (3) Outpatient or inpatient (4) Presence of symptom/findings of mycoplasma pneumonia (5) Others

Exclusion criteria

Exclusion criteria: (1) Medical history of allergy to any quinolone or macrolide antibacterial agents (2) Pregnant females, being possibly pregnant, or lactating females (3) Others

Design outcomes

Primary

MeasureTime frame
Efficacy and safety Same as above—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026